Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sunshine Biopharma Enters LNP Alliance for mRNA Macromolecule | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Sunshine Biopharma Enters LNP Alliance for mRNA Macromolecule

To conduct in vivo studies to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sunshine Biopharma, Inc., a pharmaceutical company researching life-saving medicines in oncology and antivirals, has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (LNP) companies to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1.
 
The collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma had previously shown that its K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Parallel studies using normal human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic effects.
 
The partner generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the company can advance relatively rapidly to conducting human trials. The LNP formulated K1.1 mRNA can be readily adapted for delivery into patients using the recently gained knowledge from the mRNA vaccine technology.
 
“We are delighted to be working with our new partner and their fully integrated team of experts in LNP technology,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics